This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gonzalez, L. Articles by Wang, C. Y. Search for Related Content PubMed PubMed Citation Articles by Gonzalez, L. Articles by Wang, C. Y.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, 09 1997, 598-603, Vol 4, No. 5
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Synthetic-peptide-based enzyme-linked immunosorbent assay for screening human serum or plasma for antibodies to human immunodeficiency virus type 1 and type 2

L Gonzalez, RW Boyle, M Zhang, J Castillo, S Whittier, P Della-Latta, LM Clarke, JR George, X Fang, JG Wang, B Hosein and CY Wang
United Biomedical, Inc., Hauppauge, New York 11788, USA.

A synthetic-peptide-based enzyme-linked immunosorbent assay (EIA) capable of screening for antibodies to both human immunodeficiency virus type 1 (HIV-1) and HIV-2 has been developed for use in blood banks and diagnostic laboratories. Microtiter wells are coated with two synthetic peptides, one corresponding to the highly conserved envelope region of HIV-1 and another corresponding to the conserved envelope region of HIV-2. Overall, sensitivity was 100% in 303 individuals diagnosed with AIDS and 96 individuals diagnosed with AIDS-related complex, 14.8% in a study of 500 high-risk group members, 99.9% in 600 EIA repeatedly reactive (RR)-HIV-1 Western blot (WB)-positive repository specimens, and 100% for 222 geographically diverse HIV-1 specimens and 216 confirmed HIV-2-positive specimens evaluated. The specificity was determined to be 99.72% for a total of 13,004 serum and plasma samples from random volunteer donors evaluated across five blood banks. Forty donors who were found to be EIA RR-WB indeterminate but nonreactive on the United Biomedical, Inc., test (UBI HIV 1/2 EIA) were prospectively followed as an additional measure of specificity. None of the 40 low-risk cases evolved into a positive WB pattern at follow-up. The sensitivity and specificity of this new assay are comparable to those of other Food and Drug Administration-licensed HIV-1 and HIV-1- HIV-2 assays that are currently available in the United States. The UBI HIV 1/2 EIA affords laboratories another choice in the detection of antibodies for HIV-1 and HIV-2 with a test based on an alternative antigen format.

This article has been cited by other articles:

• Iqbal, H. S., Solomon, S., Murugavel, K. G., Solomon, S. S., Balakrishnan, P. (2005). Evaluation and Diagnostic Usefulness of Domestic and Imported Enzyme-Linked Immunosorbent Assays for Detection of Human Immunodeficiency Virus Type 1 Antibody in India. CVI 12: 1425-1428 [Abstract] [Full Text]  
• Li, Z., Bai, X., Bian, H. (2002). Serologic Diagnosis of Hantaan Virus Infection Based on a Peptide Antigen. Clin. Chem. 48: 645-647 [Full Text]  
• Cordoba, P., Lanoel, A., Grutadauria, S., Zapata, M. (2000). Evaluation of Antibodies against a Rubella Virus Neutralizing Domain for Determination of Immune Status. CVI 7: 964-966 [Abstract] [Full Text]